52892 Federal Register / Vol. 72, No. 179 / Monday, September 17, 2007 / Notices 

MyoD, which is an inhibitor of the 

CDK4. CDK4 is one of a number of 

cyclin-dependent kinases which control 

progression through the cell cycle 

through their ability to phosphorylate 

particular substrates at the correct phase 

of the cell cycle. CDK4 has been shown 

to be involved in cell cycle control 

through its ability to regulate the 

activity of the retinoblastoma protein, 

pRb, an activator of genes essential for 

cell division. 

Inhibitors of the cyclin-dependent 

kinases, such as the peptides described 

in this invention, prevent cell cycle 

progression and induce cells to exit the 

cell cycle into the Go state. The peptides 

described in this invention prevent the 

phosphorylation of pRb by CDK4, an 

obligate step for entry into the cell 

cycle. Osteosarcomas and 

habdosarcomas are two types of tumors 

known to over-express pRb. The 

inhibitor described in this invention 

may be useful in treating these cancers 

or other diseases which have been 

specifically linked to over-expression of 

active pRb. 

Applications 

Method to treat proliferative 

disorders, including cancer. 

Anti-proliferative therapeutics. 

Research tool to study the cell cycle. 

Advantages: Expression of this 

peptide either as a fusion protein with 

GST or GFP results in the cessation of 

cell growth. 

Market 

An estimated 1,444,920 new cancer 

diagnoses in the U.S. in 2007. 

600,000 deaths caused by cancer in 

the U.S. in 2006. 

Cancer is the second leading cause of 

death in the United States. 

It is estimated that market for cancer 

drugs would double to $50 billion a year 

in 2010 from $25 billion in 2006. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Bruce M. Paterson and Jianmin Zhang (NCI). 

Publication: JM Zhang, et al. Coupling 

of the cell cycle and myogenesis 

through the cyclin D1-dependent 

interaction of MyoD with cdk4. EMBO 

J. 1999 Feb 15;18(4):926–933. 

Patent Status: U.S. Patent Application 

No. 10/018,964 filed 11 Apr 2002, 

claiming priority to 18 Jun 1999 (HHS 

Reference No. E–153–1998/0–US–03). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Laboratory of Biochemistry and 

Molecular Biology is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the described cdk4 

inhibitory peptides or equivalent 

peptide mimetics. Please contact John 

D. Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: September 6, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–18192 Filed 9–14–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders And Stroke; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, National 

Institute of Neurological Disorders and 

Stroke. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Neurological 

Disorders And Stroke, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

Date: September 30–October 2, 2007. 

Time: September 30, 2007, 7 p.m. to 10 

p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Susquehanna/Severn Room, 

Bethesda, MD 20814. 

Time: October 1, 2007, 8:30 a.m. to 6:30 

p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Conference Room A, Rockville, 

MD 20852. 

Time: October 2, 2007, 8:30 a.m. to 12 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Susquehanna/Severn Room, 

Bethesda, MD 20814. 

Contact Person: Alan P. Koretsky, PhD, 

Scientific Director, Division of Intramural 

Research. National Institute Of Neurological 

Disorders & Stroke, NIH, 35 Convent Drive, 

Room 6A 908, Bethesda, MD 20892, 301–

435–2232, koretskya@ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS). 

Dated: September 6, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–4566 Filed 9–14–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Nursing 

Research; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Council for Nursing 

Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who play to attend and need 

special assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Nursing Research. 

Date: September 25–26, 2007. 

Open: September 25, 2007, 1 p.m. to 5 p.m. 


jlentini on PROD1PC65 with NOTICES